Zentalis Pharmaceuticals, Inc. (ZNTL)
Stock Price:
$47.97 USD
0.17 (0.36%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.72B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
35.88M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$47.97 |
| Previous Close |
$47.80 |
| Change ($) |
0.17 |
| Change (%) |
0.36% |
| Day's Open |
48.51 |
| Day's Range |
46.00 - 48.98 |
| Day's Volume |
78,056 |
| 52-Week Range |
22.00 - 59.32 |
More Stats
| Market Cap |
1.72B |
| Enterprise Value |
1.66B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.88M |
| Float |
14.73M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.42M |
| Short Ratio |
7.91 |
| Short % of Float |
12.44% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
16.12 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
64.06M |
| Net Cash / Share |
1.79 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$44.75*
(-6.71% downside)
Low
44.0
Current: 47.97
High
45.0
Target: 44.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 0.01 |
| Gross Profit | - | 0.01 |
| Operating Income | -46.85 | -23.78 |
| Net Income | -45.66 | -21.07 |
| Shares Outstanding | 5.60 | 5.59 |
| Earnings Per Share | -8.16 | -3.77 |
| Operating Cash Flow | -39.14 | -24.25 |
| Capital Expenditures | -0.35 | -0.23 |
| Free Cash Flow | -39.50 | -24.48 |
| Cash & Equivalents | 67.49 | 25.15 |
| Net Cash / Debt | 67.49 | 25.15 |
| Assets | 87.48 | 41.00 |
| Liabilities | 19.06 | 8.69 |
| Book Value | -80.11 | 24.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zentalis Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
64 |
| CEO |
Anthony Y. Sun |
Stock Information
| Ticker Symbol |
ZNTL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ZNTL |
Description
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.